The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is part of The Ohio State University and one of the 45 National Comprehensive Cancer hospitals. It is named after Arthur G. James, the founder, who desired a cancer hospital in Columbus, Ohio, United States.

There are 306 beds in Ohio State University Comprehensive Cancer Center.

During the past decade, Ohio State University Comprehensive Cancer Center conducted 668 clinical trials. In the 10-year time frame, 668 clinical trials started and 339 clinical trials were completed, i.e. on average, 50.7% percent of trials that started reached the finish line to date. In the past 5 years, 305 clinical trials started and 176 clinical trials were completed. i.e. 57.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ohio State University Comprehensive Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 320 trials, followed by "Ohio State University Comprehensive Cancer Center" with 175 trials sponsored, "Alliance for Clinical Trials in Oncology" with 149 trials sponsored, "Gynecologic Oncology Group" with 80 trials sponsored and "Radiation Therapy Oncology Group" with 80 trials sponsored. Other sponsors include 518 different institutions and companies that sponsored additional 222 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ohio State University Comprehensive Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 544 trials as a collaborator, "NRG Oncology" with 80 trials as a collaborator, "SWOG Cancer Research Network" with 28 trials as a collaborator, "Cancer and Leukemia Group B" with 27 trials as a collaborator and "Eastern Cooperative Oncology Group" with 22 trials as a collaborator. Other collaborators include 375 different institutions and companies that were collaborators in the rest 167 trials.

According to Clinical.Site data, the most researched conditions in "Ohio State University Comprehensive Cancer Center" are "Breast Cancer" (57 trials), "Lymphoma" (54 trials), "Lung Cancer" (45 trials), "Leukemia" (35 trials) and "Ovarian Cancer" (31 trials). Many other conditions were trialed in "Ohio State University Comprehensive Cancer Center" in a lesser frequency.

Most popular intervention types in "Ohio State University Comprehensive Cancer Center" are "Drug" (964 trials), "Other" (490 trials), "Biological" (354 trials), "Procedure" (295 trials) and "Radiation" (227 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (220 trials), "Quality-of-Life Assessment" (128 trials), "Questionnaire Administration" (116 trials), "Paclitaxel" (76 trials) and "Biospecimen Collection" (73 trials). Other intervention names were less common.

The vast majority of trials in "Ohio State University Comprehensive Cancer Center" are 998 trials for "All" genders, 247 trials for "Female" genders and 63 trials for "Male" genders.

Currently, there are 566 active trials in "Ohio State University Comprehensive Cancer Center". 10 are not yet recruiting, 242 are recruiting, 311 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 563 completed trials in Ohio State University Comprehensive Cancer Center, 14 suspended trials, and 116 terminated clinical trials to date.

Out of the total trials that were conducted in Ohio State University Comprehensive Cancer Center, 290 "Phase 1" clinical trials were conducted, 608 "Phase 2" clinical trials and 323 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 126 trials that are defined as “Not Applicable".